Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of aspirin in preventing or treating colon cancer

A technology of aspirin and colon cancer, applied in the field of biomedicine, to achieve the effect of reducing the degree of slowing down

Inactive Publication Date: 2018-11-23
苏斌斌
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, aspirin is rarely reported in the literature for the prevention and treatment of colon cancer.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of aspirin in preventing or treating colon cancer
  • Application of aspirin in preventing or treating colon cancer
  • Application of aspirin in preventing or treating colon cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Embodiment 1, the experiment of aspirin to colon cancer xenograft tumor microenvironment influence

[0043] 1. Experimental materials

[0044] Experimental animals: BALB / C nude mice, 6-8 weeks old, female, weighing 25-30 g.

[0045] Experimental cells: human colorectal cancer HCT116 cell line, placed in 10% fetal bovine serum RPMI1640 culture medium, 37 ° C, 5% CO 2 Cultured, subcultured once every 2-3 days, and the cells in the logarithmic growth phase were taken for experiments.

[0046] Drug preparation: (1) Aspirin, dissolved in 0.9% normal saline, prepared as a 1.0 mg / ml solution. (2) Ticagrelor, dissolved in 500ml of 0.9% normal saline, prepared as a 1mg / ml solution.

[0047] 2. Experimental group

[0048] 1. Blank group: nude mice not inoculated with tumor + no drug treatment

[0049] 2. Control group: transplanted tumor + no drug treatment

[0050] 3. Aspirin administration group: transplanted tumor + intragastric administration of aspirin before, during a...

Embodiment 2

[0055] Embodiment 2, mouse body weight changes

[0056] 1. Experimental method

[0057] Feeding and drug treatment were carried out according to the experimental settings, and the body weight changes of the mice were measured and recorded. 2. Experimental results

[0058] figure 1 , figure 2 is the body weight change of mice in each group 7-31 days after tumor inoculation.

[0059] The results showed that, compared with the normal mice in the blank group, there was no significant difference in the body weight of the mice in each group at 7-17 days after tumor inoculation (p>0.05); at 21 days, the body weight of the control group (TI) was significantly reduced (p0.05).

Embodiment 3

[0060] Example 3, Morphological and functional evaluation of transplanted tumor microvessels

[0061] 1. Experiment preparation

[0062] Six nude mice were randomly selected in each experimental group. TRITC-dextran 100mg / kg was injected into the tail vein. 3 hours later, FITC-lectin 10mg / kg was injected into the tail vein.

[0063] 2. Experimental method

[0064] 10 minutes after the drug injection, the mice were sacrificed by dislocation of the cervical spine, the tumor mass was taken out, and frozen sections (6 μm) were immediately observed under a laser confocal microscope, and 5 non-repetitive sections were randomly selected from each section under a high-power lens (×400). The image was collected from the field of view, the vascular morphology was evaluated by FITC-lectin green fluorescence, and the vascular permeability was evaluated by the ratio of the area of ​​TRITC-dextran leaking out of the blood vessel to the total area.

[0065] 3. Experimental results

[00...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of aspirin in preventing or treating colon cancer and also relates to a medicinal composition containing the aspirin. The aspirin can relieve the decrease degree of platelet activation rate and inhibit the migration ability and invasion ability of tumor cells. The invention studies a biological regulation mechanism of the aspirin for the tumor microenvironmentof colon cancer and the medicinal effect on the colon cancer and provides a new idea for deep research and development of the aspirin and clinical treatment of the colon cancer.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of aspirin in the prevention or treatment of colon cancer. Background technique [0002] Aspirin (Aspirin, acetylsalicylic acid) is a derivative of salicylic acid. Its material property is a white crystal or crystalline powder. Ether, chloroform, aqueous solution is acidic. As early as 1853, acetylsalicylic acid was first synthesized from salicylic acid and acetic anhydride. Over the past few years, people have gradually discovered that acetylsalicylic acid has good anti-inflammatory, antipyretic and analgesic effects. Until 1899, acetylsalicylic acid began to be widely used clinically and was renamed aspirin (Aspirin). [0003] After more than 100 years of clinical application, aspirin has been proven to be effective in relieving mild or moderate pain, such as toothache, headache, neuralgia, muscle pain, joint pain and dysmenorrhea. It is also used for fever disease...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/616A61K31/519A61P1/00A61P35/00
CPCA61K31/519A61K31/616A61P1/00A61P35/00A61K2300/00
Inventor 周红霞
Owner 苏斌斌
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com